Carré Technologies Inc., also known as Hexoskin, announced on August 27, 2024 that it had raised US$4.2 million (C$5.6 million) to “invest in growth, digital biomarker research and novel AI-based digital diagnostic solutions.”
According to Hexoskin, investors in this round included “AQC Capital and Anges Quebec (Canada), BDC Capital (Canada), ballas invest (Europe), Deep Divers Ltd (UK) and 19 other US and Canadian private investors.”
Pierre-Alexandre Fournier, CEO of Hexoskin, said: “The Hexoskin team has over 15 years of experience in developing clinical AI and high-resolution wearable sensors. Our investors understand that our digital platform is uniquely positioned to develop a range of diagnostic tests and digital solutions that can address the needs of large populations in disease areas with high unmet needs, such as cardiac, respiratory and rare diseases.”
It was in 2016 when the Canadian Space Agency (CSA) announced The first contract with Carré Technologies for what was then called “Astroskin”, a bio-monitoring system. In 2019, astronaut David Saint-Jacques used the Bio-Monitor system during his long-duration mission on the International Space Station.
Also in 2019, Carré Technologies, received another CSA contract a Technology Concept Award as part of the Technology Concept Studies and Prototyping of Healthcare Technologies for Deep Space Missions – Decision Support Systems.
Hexoskin claims to have two space-wearable products, the original Astroskin and the Hexoskin. These are used in “clinical research, defense, and aerospace markets. Its customers include NASA, the Department of Defense, Yale Health, Boston Children’s Hospital, and Columbia University.” More than 250 scientific papers have been published from the data.
According to Hexoskin, its software and wearable sensors are used in ground-based applications “by clinical research teams around the world to collect digital endpoints in patient populations for a wide range of health conditions: cardiac (arrhythmias, heart rate variability), respiratory (COPD, asthma), cancer, neurology (dementia, epilepsy), rare diseases and pediatric research (Rett syndrome, ME/CFSLong Covid).
Leave feedback about this